Recent Advances in Weight Management and Healthy Eating: New Drugs, Genetics, and Policy Changes

Recent research and clinical trials over the past week have underscored significant strides in weight management through innovative pharmacological treatments, genetic testing for personalized therapies, and updates to nutrition policy targeting sugar intake. These developments present clear, quantifiable impacts on body weight, health outcomes, and dietary behavior.

Enhanced Weight Loss with Higher Dose Semaglutide

A study by UT Southwestern researchers revealed that tripling the weekly dose of semaglutide from the standard 2.4 mg to 7.2 mg led to an average weight loss of 13.2% compared to 10.4% with the lower dose. Nearly one-third (about 33%) of participants on the higher dose lost at least 25% of their starting body weight, whereas only 15% reached such weight loss with the standard dose. This demonstrates a dose-dependent enhancement in efficacy in obesity treatment.

New Oral GLP-1 Therapies Show Promising Results

Eli Lilly's novel daily oral GLP-1 receptor agonist, orforglipron, achieved an average weight loss of 27.3 pounds (12% of body weight) over 72 weeks in a global Phase 3 trial. At the highest dose of 36 mg, 54.6% of participants experienced at least 10% body weight reduction, compared to only 12.9% in the placebo group. This positions orforglipron as a potent oral alternative to injectable weekly GLP-1 therapies.

Similarly, Novo Nordisk's oral semaglutide 25 mg—representing the first oral GLP-1 drug submitted for chronic weight management—delivered mean weight loss of 16.6% over 64 weeks, with one in three participants losing 20% or more of their starting weight. These oral formulations could dramatically improve adherence and accessibility for patients avoiding injectable medications.

Genetic Testing Enables Personalized Weight Loss Treatment

Mayo Clinic researchers have developed a genetic test that predicts individual response to weight loss drugs by measuring "calories to satiation"—the food quantity needed to feel full. People with lower genetic scores lost more weight on liraglutide, a GLP-1 agonist, whereas individuals with higher scores responded better to phentermine-topiramate, an appetite suppressant combination. This new tool could tailor obesity treatments to genetic profiles, enhancing effectiveness and minimizing trial-and-error medication use.

Policy Update: Reduced Added Sugar in Child and Adult Care Programs

Effective October 1, 2025, the Child and Adult Care Food Program (CACFP) will enforce new standards limiting added sugars in breakfast cereals and yogurts served in care settings. This policy shifts from restricting total sugars to focusing specifically on added sugars, aligning with the 2020-2025 Dietary Guidelines for Americans. Such food environment changes aim to reduce sugar intake among vulnerable populations, supporting healthier dietary habits from early life stages.

Collectively, these scientific and policy advances highlight measurable improvements in weight loss outcomes, personalized medicine approaches, and preventive nutrition strategies crucial to combating obesity and fostering healthy aging.

Sources

• https://www.utsouthwestern.edu/newsroom/articles/year-2025/sept-semaglutide.html
• https://abcnews.go.com/GMA/Wellness/daily-oral-glp-1-pill-effective-weekly-shots/story?id=124440685
• https://newsnetwork.mayoclinic.org/discussion/genetic-test-predicts-response-to-weight-loss-drugs/
• https://www.biospace.com/press-releases/novo-nordisks-oral-semaglutide-25-mg-wegovy-in-a-pill-delivered-16-6-weight-loss-in-people-with-obesity-in-a-newly-published-study
• https://www.cacfp.org/2025/09/12/sweet-changes-ahead-preparing-for-cacfps-new-sugar-rules/